Document:

EX-10.2

 Exhibit 10.2 

EXECUTION VERSION 

REGISTRATION RIGHTS AGREEMENT 

BETWEEN 
 EMPIRE STATE
REALTY TRUST, INC. 
 AND 

Q REIT HOLDING LLC 

Dated as of August 23, 2016 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	Page	 
	 ARTICLE 1 DEFINED TERMS
	  	 	1	  
			
	 Section 1.1
	 	 Defined Terms
	  	 	1	  
	 Section 1.2
	 	 Table of Defined Terms
	  	 	3	  
		
	 ARTICLE 2 SHELF REGISTRATION
	  	 	3	  
			
	 Section 2.1
	 	 Shelf Registration
	  	 	3	  
	 Section 2.2
	 	 Effectiveness
	  	 	4	  
	 Section 2.3
	 	 Notification and Distribution of Materials
	  	 	4	  
	 Section 2.4
	 	 Amendments and Supplements
	  	 	4	  
	 Section 2.5
	 	 New York Stock Exchange
	  	 	4	  
	 Section 2.6
	 	 Notice of Certain Events
	  	 	5	  
		
	 ARTICLE 3 SUSPENSION OF REGISTRATION REQUIREMENTS; SALES RESTRICTIONS
	  	 	6	  
			
	 Section 3.1
	 	 Suspension of Registration Requirements
	  	 	6	  
	 Section 3.2
	 	 Restriction on Sales
	  	 	6	  
	 Section 3.3
	 	 Market Stand-Off
	  	 	7	  
		
	 ARTICLE 4 INDEMNIFICATION
	  	 	8	  
			
	 Section 4.1
	 	 Indemnification by the Company
	  	 	8	  
	 Section 4.2
	 	 Indemnification by the Holder
	  	 	8	  
	 Section 4.3
	 	 Notices of Claims, etc.
	  	 	9	  
	 Section 4.4
	 	 Indemnification Payments
	  	 	10	  
	 Section 4.5
	 	 Contribution
	  	 	10	  
		
	 ARTICLE 5 TERMINATION; SURVIVAL
	  	 	10	  
			
	 Section 5.1
	 	 Termination; Survival
	  	 	10	  
		
	 ARTICLE 6 MISCELLANEOUS
	  	 	11	  
			
	 Section 6.1
	 	 Covenants Relating to Rule 144
	  	 	11	  
	 Section 6.2
	 	 No Conflicting Agreements
	  	 	11	  
	 Section 6.3
	 	 Additional Shares
	  	 	11	  
	 Section 6.4
	 	 Governing Law; Arbitration
	  	 	11	  
	 Section 6.5
	 	 Counterparts
	  	 	12	  
	 Section 6.6
	 	 Headings
	  	 	12	  
	 Section 6.7
	 	 Severability
	  	 	12	  
	 Section 6.8
	 	 Entire Agreement; Amendments; Waiver
	  	 	12	  
	 Section 6.9
	 	 Notices
	  	 	12	  
	 Section 6.10
	 	 Successors and Assigns
	  	 	13	  
	 Section 6.11
	 	 No Third Party Beneficiaries
	  	 	14	  
	 Section 6.12
	 	 Further Assurances
	  	 	14	  
	 Section 6.13
	 	 Specific Performance
	  	 	14	  
	 Section 6.14
	 	 Costs and Expenses
	  	 	14	  

  
 i 

 REGISTRATION RIGHTS AGREEMENT 

This REGISTRATION RIGHTS AGREEMENT (as the same may be amended, modified or supplemented from time to time, this
“Agreement”), dated as of August 23, 2016, is made and entered into by and between Empire State Realty Trust, Inc., a Maryland corporation (the “Company”), and Q REIT Holding LLC, a Qatar Financial
Centre limited liability company (the “Holder”). 
 WHEREAS, the Holder wishes to purchase, and the Company wishes
to issue, that aggregate number of shares of the Company’s Class A common stock, par value $0.01 per share (the “Common Stock”), set forth opposite the Holder’s name in column (3) on Schedule 1 hereto
(the “Purchased Shares”), upon the terms and conditions set forth in that certain Securities Purchase Agreement, of even date herewith (the “Purchase Agreement”), relating to the Purchased Shares. 

WHEREAS, the Holder and the Company are also entering into a Stockholders Agreement, an Ownership Limitation Waiver and related
Purchaser Representation Letter, each of even date herewith (such agreements and documents, together with the Purchase Agreement, the “Related Documents”); 

WHEREAS, the Company desires to enter into this Agreement with the Holder in order to grant the Holder the registration rights
contained herein. 
 NOW, THEREFORE, in consideration of the mutual representations, warranties, covenants and agreements contained
in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Holder hereby agree as follows: 

ARTICLE 1 
 DEFINED
TERMS 
 Section 1.1 Defined Terms. The following definitions shall be for all purposes, unless otherwise clearly indicated
to the contrary, applied to the terms used in this Agreement. 
 “Automatic Shelf Registration Statement” means an
“Automatic Shelf Registration Statement,” as defined in Rule 405 under the Securities Act. 
 “Business Day”
means any day except a Saturday, Sunday or other day on which commercial banks in New York, New York are authorized or required by law to be closed. 

“Commission” means the U.S. Securities and Exchange Commission. 

“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended (or any corresponding provision of succeeding law)
and the rules and regulations thereunder. 
 “Person” means any individual, partnership, corporation, limited liability
company, joint venture, association, trust, unincorporated organization or other governmental or legal entity. 

 “Prospectus” means the prospectus or prospectuses included in any Registration
Statement (including without limitation, any prospectus subject to completion and a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A
promulgated under the Securities Act and any term sheet filed pursuant to Rule 434 under the Securities Act), as amended or supplemented by any prospectus supplement with respect to the terms of the offering of any portion of the Registrable
Shares covered by such Registration Statement and by all other amendments and supplements to the prospectus, including post-effective amendments and all material incorporated by reference or deemed to be incorporated by reference in such prospectus
or prospectuses. 
 “Registrable Shares” with respect to the Holder, means at any time (i) the Purchased Shares,
(ii) any Top Up Shares acquired from time to time pursuant to the Stockholders Agreement, and (iii) any other shares of Common Stock acquired by the Holder from time to time not in excess of, or ownership of fully diluted economic
interests in the Company in violation of, a restriction or limit on such ownership as set forth in any of the Related Documents, including, in each case, any additional shares of Common Stock or other equity securities issued as a dividend or
distribution on, in exchange for, or otherwise in respect of, shares that otherwise constitute Registrable Shares (including as a result of combinations, recapitalizations, mergers, consolidations, reorganizations or otherwise); provided,
however, that Registrable Shares shall cease to be Registrable Shares with respect to the Holder upon the earliest to occur of (A) when such Registrable Shares shall have been disposed of pursuant to a Registration Statement,
(B) when all of the Holder’s Registrable Shares may be sold without restriction pursuant to Rule 144(b) under the Securities Act or any replacement rule or (C) when the Holder’s Registrable Shares shall have ceased to be
outstanding. 
 “Registration Expenses” means any and all expenses incident to the performance of or compliance with this
Agreement, which shall be borne by the Company as provided below, including without limitation: (i) all registration and filing fees, (ii) printing expenses, (iii) internal expenses of the Company (including, without limitation, all
salaries and expenses of its officers and employees performing legal or accounting duties), (iv) the fees and expenses incurred in connection with the listing of the Registrable Shares, (v) the fees and disbursements of legal counsel for
the Company and customary fees and expenses for independent certified public accountants retained by the Company, and any transfer agent and registrar fees and (vi) the reasonable fees and expenses of any special experts retained by the
Company; provided, however, that “Registration Expenses” shall not include, and the Company shall not have any obligation to pay, any underwriting fees, discounts, commissions, or taxes (including transfer taxes)
attributable to the sale of securities by the Holder, or any legal fees and expenses of counsel to the Holder and any underwriter engaged by Holder or any other expenses incurred in connection with the performance by the Holder of their obligations
under the terms of this Agreement. 
 “Registration Statement” means any registration statement of the Company filed with
the Commission under the Securities Act which covers any of the Registrable Shares pursuant to the provisions of this Agreement, including the Prospectus, amendments and supplements to such Registration Statement, including post-effective
amendments, all exhibits and all materials incorporated by reference or deemed to be incorporated by reference in such Registration Statement. 

  
 2 

 “Securities Act” means the U.S. Securities Act of 1933, as amended (or any
corresponding provision of succeeding law) and the rules and regulations thereunder. 
 “Stockholders Agreement” means that
certain Stockholders Agreement, of even date herewith, by and between the Company and the Holder. 
 “Top Up Shares” shall
have the meaning given to such term in the Stockholders Agreement. 
 Section 1.2 Table of Defined Terms. Terms that are not
defined in Section 1.1 have the respective meanings set forth in the following Sections: 
  

			
	 Defined Term
	  	
SECTION NO.

	Agreement	  	Preamble
	Common Stock	  	Recitals
	Company	  	Preamble
	Company Offering	  	Section 3.2(b)
	Controlling Person	  	Section 4.1
	Holder	  	Preamble
	Liabilities	  	Section 4.1(a)
	Offering Blackout Period	  	Section 3.2(b)
	Purchase Agreement	  	Recitals
	Purchased Shares	  	Recitals
	Related Documents	  	Recitals
	Suspension Event	  	Section 3.1(b)

 ARTICLE 2 

SHELF REGISTRATION 

Section 2.1 Shelf Registration. The Company agrees to use commercially reasonable efforts to file, on or before the date that is
180 days after the date of this Agreement, with the Commission a Registration Statement on an appropriate form (which shall be, if the Company is then eligible, an Automatic Shelf Registration Statement) providing for the registration of, and the
sale by Holder of, all of the Registrable Shares held by the Holder at the time of such filing on a continuous or delayed basis by the Holder, from time to time in accordance with the methods of distribution elected by the Holder, pursuant to Rule
415 under the Securities Act or any similar rule that may be adopted by the Commission; provided, however, that the number of shares of Registrable Securities included in the Registration Statement at any time may not exceed 9.9% of
the fully diluted economic interests (as such term is defined in the Stockholders Agreement) in the Company. If the Registration Statement is not an Automatic Shelf Registration Statement, the Company will use commercially reasonable efforts to
cause the Registration Statement to be declared effective by the Commission as soon as practicable after 

  
 3 

 
the filing thereof. To the extent that the Company has an effective shelf registration statement on file and effective with the Commission at the time it is going to file a Registration Statement
hereunder, the Company may (but will not be required to) instead file a prospectus or post-effective amendment, as applicable, to include in such shelf registration statement the Registrable Shares to be registered pursuant to this Agreement (in
such a case, such prospectus or post-effective amendment together with the previously filed shelf registration statement will be considered the Registration Statement). 

Section 2.2 Effectiveness. The Company shall use commercially reasonable efforts to keep the Registration Statement continuously
effective (or in the event the Registration Statement expires pursuant to Rule 415(a)(5) under the Securities Act, file a replacement Registration Statement and keep such replacement Registration Statement effective) for the period beginning on the
date on which the Registration Statement is declared or becomes effective and ending on the date that no Registrable Shares remain as Registrable Shares. 

Section 2.3 Notification and Distribution of Materials. The Company shall notify the Holder of the effectiveness of any
Registration Statement applicable to the Purchased Shares and shall furnish to the Holder such number of copies of such Registration Statement (including any amendments, supplements and exhibits), the Prospectus contained therein (including each
preliminary prospectus and all related amendments and supplements, if any) and any documents incorporated by reference in such Registration Statement or such other documents as the Holder may reasonably request in order to facilitate the sale of the
Registrable Shares in the manner described in such Registration Statement. 
 Section 2.4 Amendments and Supplements. During the
period that the Registration Statement is effective, the Company shall prepare and file with the Commission from time to time such amendments and supplements to the Registration Statement and Prospectus used in connection therewith as may be
necessary to keep such Registration Statement (or a successor Registration Statement filed with respect to such Registrable Shares) effective and to comply with the provisions of the Securities Act with respect to the disposition of the Registrable
Shares covered thereby. Upon reasonable request of the Holder, the Company shall use its commercially reasonable efforts to file, within twenty (20) Business Days, any supplement or post-effective amendment to the Registration
Statement with respect to the plan of distribution as specified by the Holder, to add Registrable Shares to the Registration Statement as a result of the issuance of Top Up Shares pursuant to the Stockholders Agreement, or as is otherwise reasonably
necessary to permit the sale of the Holder’s Registrable Shares pursuant to such Registration Statement; provided, that the Holder may not make more than two (2) such requests for the Company to file a supplement or post-effective
amendment to the Registration Statement in any 12-month period. The Company shall use its commercially reasonable efforts to have such supplements and amendments declared effective, if required, as soon as practicable after filing. The Holder agrees
to deliver such notices, questionnaires and other information as the Company may reasonably request in writing, if any, to the Company at least fifteen (15) Business Days prior to the anticipated filing or effective date, as applicable, of any
supplement or post-effective amendment to the Registration Statement. 
 Section 2.5 New York Stock Exchange. The Company shall
file any necessary listing applications or amendments to the existing applications to cause the Registrable Shares 

  
 4 

 
registered under any Registration Statement to be then listed or quoted on the New York Stock Exchange or such other primary exchange or quotation system on which the Common Stock is then listed
or quoted. 
 Section 2.6 Notice of Certain Events. 

(a) The Company shall promptly notify the Holder in writing of the filing of any Registration Statement or Prospectus, amendment or supplement
related thereto or any post-effective amendment to a Registration Statement and the effectiveness of any post-effective amendment, provided, however, that this Section 2.6(a) shall not apply to (i) an amendment or
supplement relating solely to securities other than the Registrable Shares, and (ii) an amendment or supplement by means of an Annual Report on Form 10-K, a Quarterly Report on Form 10-Q, a Proxy Statement on Schedule 14A, a Current Report on
Form 8-K or a Registration Statement on Form 8-A or any amendments thereto filed with the Commission under the Exchange Act and incorporated or deemed to be incorporated by reference into a Registration Statement or Prospectus. 

(b) At any time when a Prospectus relating to a Registration Statement is required to be delivered under the Securities Act by the Holder to a
transferee, the Company shall immediately notify the Holder of the happening of any event as a result of which the Company believes the Prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material
fact or omits to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. In such event, the Company shall promptly prepare and, if
applicable, furnish to the Holder a reasonable number of copies of a supplement to or an amendment of such Prospectus as may be necessary so that, as thereafter delivered to the purchasers of Registrable Shares sold under the Prospectus, such
Prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they are made, not misleading.
The Company shall, if necessary, promptly amend the Registration Statement of which such Prospectus is a part to reflect such amendment or supplement. The Holder agrees that, upon receipt of any notice from the Company of the occurrence of an event
as set forth above, the Holder will forthwith discontinue disposition of Registrable Shares pursuant to any Registration Statement covering such Registrable Shares until the Holder’s receipt of written notice from the Company that the use of
the Registration Statement may be resumed. The Holder also agrees that it will treat as confidential the receipt of any notice from the Company of the occurrence of an event as set forth above and shall not disclose or use the information contained
in such notice without the prior written consent of the Company until such time as the information contained therein is or becomes available to the public generally, other than as a result of disclosure by the Holder in breach of the terms of this
Agreement. 

  
 5 

 ARTICLE 3 

SUSPENSION OF REGISTRATION 

REQUIREMENTS; SALES RESTRICTIONS 

Section 3.1 Suspension of Registration Requirements. 

(a) The Company shall promptly notify the Holder in writing of the issuance by the Commission or any state instrumentality of any stop order
suspending the effectiveness of a Registration Statement with respect to the Holder’s Registrable Shares or the initiation of any proceedings for that purpose. The Company shall use its reasonable efforts to obtain the withdrawal of any order
suspending the effectiveness of such a Registration Statement as promptly as practicable after the issuance thereof. 
 (b) Notwithstanding
anything to the contrary set forth in this Agreement, the Company’s obligation under this Agreement to file, amend or supplement a Registration Statement, or to cause a Registration Statement, or any filings under any state securities laws, to
become or remain effective shall be suspended, as the Company may reasonably determine necessary and advisable (but in no event for more than an aggregate of 120 days in any rolling 12-month period commencing on the date of this Agreement or more
than 60 consecutive days, except as a result of a refusal by the Commission to declare any post-effective amendment to the Registration Statement effective after the Company has used all commercially reasonable efforts to cause the post-effective
amendment to be declared effective by the Commission, in which case, the Company must terminate the black-out period immediately following the effective date of the post-effective amendment) in the event of pending negotiations relating to, or
consummation of, a transaction or the occurrence of an event that (i) would require additional disclosure of material information by the Company in the Registration Statement or such filing, as to which the Company has a bona fide business
purpose for preserving confidentiality, or (ii) render the Company unable to comply with Commission requirements, or (iii) would otherwise make it impractical or unadvisable to cause the Registration Statement or such filings to be filed,
amended or supplemented or to become effective (any such circumstances being hereinafter referred to as a “Suspension Event”). The Company shall notify the Holder of the existence of any Suspension Event by promptly delivering to
the Holder a certificate signed by an executive officer of the Company stating that a Suspension Event has occurred and is continuing. The Holder agrees that it will treat as confidential the receipt of any notice from the Company of the occurrence
of an event as set forth above and shall not disclose or use the information contained in such notice without the prior written consent of the Company until such time as the information contained therein is or becomes available to the public
generally, other than as a result of disclosure by the Holder in breach of the terms of this Agreement. 
 Section 3.2 Restriction
on Sales. 
 (a) The Holder agrees that, following the effectiveness of any Registration Statement relating to its Registrable Shares,
the Holder will not effect any dispositions of any of the Purchased Shares pursuant to such Registration Statement or any filings under any state securities laws at any time after the Holder has received notice from the Company to suspend
dispositions as a result of the occurrence or existence of any Suspension Event or so that the Company may correct or update the Registration Statement or such filing. The Holder will maintain the confidentiality of any information included in the
written notice delivered by the Company unless otherwise required by law or subpoena. The Holder may recommence effecting dispositions of the Purchased Shares pursuant to the Registration Statement or such filings, and all other obligations which
are suspended as a result of a Suspension Event shall no longer be so suspended, following further notice to such effect from the Company, which notice shall be given by the Company promptly after the conclusion of any such Suspension Event. 

  
 6 

 (b) The Holder of Registrable Shares further agrees, if requested by the managing underwriter or
underwriters in a Company-initiated underwritten offering (each, a “Company Offering”), not to effect any disposition of any of the Purchased Shares during the period (the “Offering Blackout Period”) beginning upon
receipt by the Holder of written notice from the Company, but in any event no earlier than the fifteenth (15th) day preceding the anticipated date of pricing of such Company Offering, and ending no later than ninety (90) days after the
closing date of such Company Offering. Such Offering Blackout Period notice shall be in writing in the form reasonably satisfactory to the Company and the managing underwriter or underwriters. The Holder will maintain the confidentiality of any
information included in such notice delivered by the Company unless otherwise required by law or subpoena. 
 Section 3.3 Market
Stand-Off. 
 (a) The Holder hereby agrees that (for so long as the Holder files Forms 3, 4 or 5 in accordance with Section 16 of
the Exchange Act (or similar successor forms established by the Commission) solely in its capacity as a stockholder of the Company) it shall not, directly or indirectly sell, offer to sell (including without limitation any short sale), pledge,
contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of or otherwise dispose of or transfer any Registrable Shares or other Common Stock or any securities
convertible into or exchangeable or exercisable for Common Stock then owned by the Holder for up to 60 days following the date of an underwriting agreement with respect to an underwritten public offering of the Company’s securities;
provided, however, that: 
 (i) all officers and directors of the Company then holding Common Stock or
securities convertible into or exchangeable or exercisable for Common Stock enter into similar agreements for not less than the entire time period required of the Holder hereunder; and 

(ii) the Holder shall be allowed any concession or proportionate release allowed to any (A) officer, (B) director or
(C) other holder of the Company’s Common Stock that entered into similar agreements (with such proportion being determined by dividing the number of shares being released with respect to such officer, director or other holder of the
Company’s Common Stock by the total number of issued and outstanding shares held by such officer, director or holder). 
 (b) In order
to enforce the foregoing covenant, the Company shall have the right to place restrictive legends on the certificates representing the securities subject to this Section 3.3 and to impose stop transfer instructions with respect to the
Registrable Shares and such other securities of the Holder (and the securities of every other Person subject to the foregoing restriction) until the end of such period. 

  
 7 

 ARTICLE 4 

INDEMNIFICATION 

Section 4.1 Indemnification by the Company. The Company agrees to indemnify and hold harmless the Holder, and the officers,
directors, stockholders, members, managers, partners, trustees, employees, representatives and agents of the Holder, and each Person (a “Controlling Person”), if any, who controls (within the meaning of Section 15(a) of the
Securities Act or Section 20(a) of the Exchange Act) any of the foregoing Persons, as follows (to the fullest extent permitted by applicable law): 

(a) from and against any and all cost, loss, liability, obligation, claim, damage, judgment, award, actions, other liabilities and expense
whatsoever (the “Liabilities”), as incurred by any of them, arising out of or in connection with (A) any untrue statement or alleged untrue statement of a material fact contained in any Registration Statement (or any amendment
or supplement thereto) pursuant to which Registrable Shares were registered under the Securities Act, including all documents incorporated therein by reference, or the omission or alleged omission therefrom of a material fact required to be stated
therein or necessary to make the statements therein not misleading, or (B) any untrue statement or alleged untrue statement of a material fact contained in any Prospectus (or any amendment or supplement thereto) or the omission or alleged
omission therefrom at such date of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; 

(b) from and against any and all Liabilities, as incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any
investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided that (subject to
Section 4.4 below) any such settlement is effected with the prior written consent of the Company; and 
 (c) from and against
any and all legal or other expenses whatsoever, as incurred (including the reasonable fees and disbursements of one counsel chosen by any indemnified party, at standard rates not in excess of those paid by such indemnified party in the ordinary
course of its business), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such
untrue statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under subparagraph (i) or (ii) above; 

provided, however, that this indemnity agreement shall not apply to any Liabilities to the extent arising out of any untrue statement or
omission or alleged untrue statement or omission made in reliance upon and in conformity with written information furnished to the Company by the Holder expressly for use in a Registration Statement (or any amendment thereto) or any Prospectus (or
any amendment or supplement thereto). 
 Section 4.2 Indemnification by the Holder. The Holder agrees to indemnify and hold
harmless the Company, and the officers, directors, stockholders, members, partners, managers, employees, trustees, executors, representatives and agents of the Company, and each of their respective Controlling Persons, to the fullest extent
permitted by applicable law, from and against any and all Liabilities described in the indemnity contained in Section 4.1 hereof, as 

  
 8 

 
incurred, but only with respect to untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement (or any amendment thereto) or any Prospectus
included therein (or any amendment or supplement thereto) in reliance upon and in conformity with written information with respect to the Holder furnished to the Company by the Holder expressly for use in the Registration Statement (or any amendment
thereto) or such Prospectus (or any amendment or supplement thereto); provided, however, that the Holder shall not be liable for any claims hereunder in excess of the amount of net proceeds (after deducting underwriters’ discounts
and commissions) received by the Holder from the sale of Registrable Shares pursuant to such Registration Statement. 
 Section 4.3
Notices of Claims, etc.. Each indemnified party shall give notice as promptly as reasonably practicable to each indemnifying party of any action or proceeding commenced against it in respect of which indemnity may be sought hereunder, but
failure to so notify an indemnifying party shall not relieve such indemnifying party from any liability hereunder unless the indemnifying party is actually materially prejudiced as a result thereof, and in such case, only to the extent of such
prejudice, and in any event shall not relieve it from any liability which it may have otherwise than on account of this indemnity agreement. An indemnifying party may participate therein at its own expense and, to the extent that it shall wish,
assume the defense of such action; provided, however, that counsel to the indemnifying party shall not (except with the consent of the indemnified party) also be counsel to the indemnified party. Notwithstanding the indemnifying
party’s rights in the immediately preceding sentence, the indemnified party shall have the right to employ its own counsel (in addition to any local counsel), and the indemnifying party shall bear the reasonable fees, costs, and expenses of
such separate counsel if (a) the use of counsel chosen by the indemnifying party to represent the indemnified party would present such counsel with a conflict of interest; (b) actual or potential defendants in, or targets of, any such
proceeding include both the indemnified party and the indemnifying party, and the indemnified party shall have reasonably concluded that there may be legal defense available to it and/or other indemnified parties which are different from or
additional to those available to the indemnified party; (c) the indemnifying party shall not have employed counsel to represent the indemnified party within a reasonable time after notice of the institution of such proceeding; or (d) the
indemnifying party shall authorize the indemnified party to employ separate counsel at the expense of the indemnifying party. In no event shall the indemnifying party or parties be liable for the fees and expenses of more than one counsel (in
addition to any local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate but similar or related actions in the same jurisdiction arising out of the same general allegations or
circumstances. No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise or consent to the entry of any judgment with respect to any litigation, or any investigation or proceeding by any
governmental agency or body, commenced or threatened, or any claim whosoever in respect of which indemnification or contribution could be sought under this Article 4 (whether or not the indemnified parties are actual or potential parties
thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and (ii) does not include a
statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified party. 

  
 9 

 Section 4.4 Indemnification Payments. If at any time an indemnified party shall have
requested an indemnifying party consent to any settlement of the nature contemplated by Section 4.1(b), such indemnifying party agrees that it shall be liable for such settlement, including any such related fees and expenses of counsel,
effected without its written consent if (i) such settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall have received notice of the terms of
such settlement at least 30 days prior to such settlement being entered into, and (iii) such indemnifying party shall not have responded to such indemnified party in accordance with such request prior to the date of such settlement. 

Section 4.5 Contribution. 

(a) If the indemnification provided for in this Article 4 is for any reason unavailable to or insufficient to hold harmless an
indemnified party in respect of any Liabilities referred to therein, then each indemnifying party shall contribute to the aggregate amount of such Liabilities incurred by such indemnified party, as incurred, in such proportion as is appropriate to
reflect the relative fault of the Company on the one hand and the Holder on the other hand in connection with the statements or omissions which resulted in such Liabilities, as well as any other relevant equitable considerations. 

(b) The relative fault of the Company on the one hand and the Holder on the other hand shall be determined by reference to, among other
things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or the Holder and the parties’ relative intent, knowledge,
access to information and opportunity to correct or prevent such statement or omission. 
 (c) The Company and the Holder agree that it
would not be just and equitable if contribution pursuant to this Section 4.5 were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to above in
this Article 4. The aggregate amount of Liabilities incurred by an indemnified party and referred to above in this Article 4 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in
investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission
or alleged omission. 
 (d) No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. 
 ARTICLE
5 
 TERMINATION; SURVIVAL 

Section 5.1 Termination; Survival. The rights of the Holder under this Agreement shall terminate upon the earlier of the date
(i) that all of the Registrable Shares cease to be 

  
 10 

 
Registrable Shares, or (ii) the Holder ceases to beneficially own the Minimum Ownership Percentage (as such term is defined in the Stockholders Agreement). Notwithstanding the foregoing, the
obligations of the parties under Section 3.3, Article 4 and Article 6 of this Agreement shall remain in full force and effect following such time. 

ARTICLE 6 

MISCELLANEOUS 

Section 6.1 Covenants Relating to Rule 144. For so long as the Company is subject to the reporting requirements of Section 13
or 15 of the Exchange Act, the Company covenants that it will file the reports required to be filed by it under the Securities Act and Section 13(a) or 15(d) of the Exchange Act and the rules and regulations adopted by the Commission
thereunder. If the Company ceases to be so required to file such reports, the Company covenants that it will upon the request of the Holder of Registrable Shares (a) make publicly available such information as is necessary to permit sales
pursuant to Rule 144 under the Securities Act, (b) deliver such information to a prospective purchaser as is necessary to permit sales pursuant to Rule 144A under the Securities Act and it will take such further action as the Holder
of Registrable Shares may reasonably request, and (c) take such further action that is reasonable in the circumstances, in each case to the extent required from time to time to enable the Holder to sell its Registrable Shares without
registration under the Securities Act within the limitation of the exemptions provided by (i) Rule 144 under the Securities Act, as such Rule may be amended from time to time, (ii) Rule 144A under the Securities Act, as such rule
may be amended from time to time, or (iii) any similar rules or regulations hereafter adopted by the Commission. Upon the request of the Holder of Registrable Shares, the Company will deliver to the Holder a written statement as to whether it
has complied with such requirements and of the Securities Act and the Exchange Act, a copy of the most recent annual and quarterly report(s) of the Company, and such other reports, documents or stockholder communications of the Company, and
take such further actions consistent with this Section 6.1, as the Holder may reasonably request in availing itself of any rule or regulation of the Commission allowing the Holder to sell any such Registrable Shares without registration.

 Section 6.2 No Conflicting Agreements. The Company has not entered into and the Company will not after the date of this
Agreement enter into any agreement which conflicts with the rights granted to the Holders of Registrable Shares pursuant to this Agreement or otherwise conflicts with the provisions of this Agreement. The rights granted to the Holders hereunder do
not and will not for the term of this Agreement in any way conflict with the rights granted to the holders of the Company’s other issued and outstanding securities under any such agreements. 

Section 6.3 Additional Shares. The Company, at its option, may register, under any Registration Statement and any filings under
any state securities laws filed pursuant to this Agreement, any number of unissued, treasury or other Common Stock of or owned by the Company and any of its subsidiaries or any Common Stock or other securities of the Company owned by any other
security holder or security holders of the Company. 
 Section 6.4 Governing Law; Arbitration. All questions concerning the
construction, validity, enforcement and interpretation of this Agreement shall be governed by, and shall be 

  
 11 

 
construed and interpreted in accordance with, the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of
New York or any other jurisdictions) that would cause the application of the laws of any jurisdiction other than the State of New York. Any action or proceedings brought by a party to recover damages in respect of any disagreement or dispute in
connection with this Agreement shall be submitted to and finally settled by arbitration in accordance with the rules and procedures of the American Arbitration Association, through its International Centre for Dispute Resolution before a panel of
three arbitrators selected in accordance with such rules. The site of any such arbitration shall be Manhattan, New York, New York or such other place as the Company and the Holder shall agree at the time, and the proceedings shall be conducted in
the English language. Any such arbitration award obtained pursuant to this clause shall be final and binding on the parties. The parties undertake to carry out any award without delay, and the parties agree that judgment upon any such award may be
entered by any court having jurisdiction over the matter or the relevant party or its assets. Notwithstanding the foregoing, the request by either party for injunctive relief or specific performance shall not be subject to arbitration and may be
adjudicated only by the courts of the State of New York located in Manhattan, New York, New York, or the United States District Court of the Southern District of New York. 

Section 6.5 Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided, that a signature delivered by facsimile, email pdf or other electronic form shall be considered
due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original. 

Section 6.6 Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the
interpretation of, this Agreement. 
 Section 6.7 Severability. If any provision of this Agreement shall be invalid or
unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability of any provision of this Agreement in
any other jurisdiction. 
 Section 6.8 Entire Agreement; Amendments; Waiver. This Agreement and the Related Documents supersede
all other prior oral or written agreements between the Holder, the Company, their affiliates and Persons acting on their behalf with respect to the matters discussed herein, and this Agreement and the Related Documents contain the entire
understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Holder makes any representation, warranty, covenant or undertaking with respect
to such matters. No provision of this Agreement may be amended other than by an instrument in writing signed by the Company and the Holder. No provision hereof may be waived other than by an instrument in writing signed by the party against whom
enforcement is sought. 
 Section 6.9 Notices. Any notices, consents, waivers or other communications required or permitted to
be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon receipt, 

  
 12 

 
when sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); or (iii) one Business Day after deposit with
an overnight courier service, in each case properly addressed to the party to receive the same. The addresses and facsimile numbers for such communications shall be: 

If to the Company: 
 Empire
State Realty Trust, Inc. 
 111 West 33rd Street, 12th Floor 
 New York, New York 10120 

Attention: Thomas N. Keltner Jr. and Bart S. Goldstein 

Facsimile: 212-986-7679 
 with a
copy (for informational purposes only) to: 
 Goodwin Procter LLP 

The New York Times Building 
 620
Eighth Avenue 
 New York, New York 10018 

Attention: Yoel Kranz 
 Facsimile:
212-813-8831 
 If to the Holder, to its address and facsimile number set forth on Schedule 1 hereto, with copies (for
informational purposes) to the Holder’s representatives as set forth on Schedule 1 hereto and to such other address and/or facsimile number and/or to the attention of such other Person as the Holder has specified by written notice
given to the Company five (5) days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent, waiver or other communication, (B) mechanically or electronically
generated by the sender’s facsimile machine containing the time, date, recipient facsimile number and an image of the first page of such transmission or (C) provided by an overnight courier service shall be rebuttable evidence of personal
service, receipt by facsimile or receipt from an overnight courier service in accordance with clause (i), (ii) or (iii) above, respectively. The Holder hereby appoints QIA Advisory (USA) Inc., 9 West 57th Street,
34th Floor, New York, NY 10019 as its agent for the service of process in the United States. 
 Section 6.10 Successors and
Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their respective permitted successors and assigns. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior
written consent of the Holder. The Holder shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Company, in which event such assignee shall be deemed to be the Holder hereunder with respect
to such assigned rights and obligations. Notwithstanding the above, nothing herein shall be deemed to permit any assignment, transfer or other disposition of Registrable Shares in violation of the terms of the Purchase Agreement or the other Related
Documents. If any transferee of the Holder shall acquire Registrable Shares, in any manner, whether by operation of law or otherwise, such Registrable Shares shall be held subject to all of the terms of this Agreement, and by taking and holding such
Registrable Shares such Person shall be conclusively deemed to have agreed to be bound by and to perform all of 

  
 13 

 
the terms and provisions of this Agreement, including the restrictions on resale set forth in this Agreement and, if applicable, the Purchase Agreement and the other Related Documents, and such
Person shall be entitled to receive the benefits hereof. 
 Section 6.11 No Third Party Beneficiaries. This Agreement is
intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person other than as expressly set forth in Article 4
and this Section 6.11. 
 Section 6.12 Further Assurances. Each party shall do and perform, or cause to be done and
performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the intent and accomplish the purposes of
this Agreement and the consummation of the transactions contemplated hereby. 
 Section 6.13 Specific Performance. The parties
acknowledge and agree that in the event of a breach or threatened breach of its covenants hereunder, the harm suffered would not be compensable by monetary damages alone and, accordingly, in addition to other available legal or equitable remedies,
each non-breaching party shall be entitled to apply for an injunction or specific performance with respect to such breach or threatened breach, without proof of actual damages (and without the requirement of posting a bond, undertaking or other
security), and the Holder and the Company agree not to plead sufficiency of damages as a defense in such circumstances. 
 Section 6.14
Costs and Expenses. The Company shall bear all Registration Expenses incurred in connection with the registration of the Registrable Shares pursuant to this Agreement and the Company’s performance of its other obligations under the terms
of this Agreement. The Holder shall bear all underwriting fees, discounts, commissions, or taxes (including transfer taxes) attributable to the sale of securities by the Holder, or any legal fees and expenses of counsel to the Holder and any
underwriter engaged by Holder and all other expenses incurred in connection with the performance by the Holder of their obligations under the terms of this Agreement. All other costs and expenses incurred in connection with this Agreement and the
transactions contemplated hereby will be paid by the party incurring such costs and expenses, whether or not any of the transactions contemplated hereby are consummated. 

[Signature Page Follows] 

  
 14 

 IN WITNESS WHEREOF, the Holder and the Company have caused their respective signature page
to this Agreement to be duly executed as of the date first written above. 
  

			
	EMPIRE STATE REALTY TRUST, INC.
		
	By:	 	 /s/ David A. Karp

	Name:	 	David A. Karp
	Title:	 	Executive Vice President and Chief
		 	Financial Officer
	
	Q REIT HOLDING LLC
		
	By:	 	 /s/ Ahmad Al-Khanji

	Name:	 	Ahmad Al-Khanji
	Title:	 	Director

  
 [Signature Page to
Registration Rights Agreement] 

 SCHEDULE 1 
  

 

							
	 (1)
	 	 (2)
	 	 (3)
	 	 (4)

	 Holder
	 	 Address, Facsimile

Number and

Jurisdiction
	 	 Number of

Purchased

Shares
	 	 Legal Representative’s

Address and Email

	Q REIT Holding LLC	 	 Ooredoo Tower, Diplomatic Area Street, West Bay, Doha P.O. Box 23224, Qatar

Facsimile: 974 4459 5990
	 	29,610,854	 	 White & Case LLP
 1155 Avenue of

the Americas
 New York, New York 10036

Attention: Oliver Brahmst Email: obrahmst@whitecase.com

  
 Schedule 1Exhibit 10.1

 

 

August 22, 2016

 

Bradley Campbell

16 Morris Drive

Princeton, NJ, 08540 USA

 

Dear Bradley:

 

This secondment letter (“the Agreement”) sets out the terms of your secondment to Amicus Therapeutics UK Limited (“the Company”) in Gerrard’s Cross, UK. It also details the variations to your Employment Agreement with Amicus Therapeutics, Inc., (“Amicus Therapeutics”) dated April 23, 2014 (“the Employment Agreement”), which will apply for the duration of the secondment.

 

Preconditions

 

The secondment is conditional upon your having a valid visa/work permit allowing you to work legally in the UK. Some further information about immigration support available to you is set out below. Please note that any dependents accompanying you to the UK will also require entry clearance before travelling.

 

Term of secondment

 

Your secondment to the Company will be effective as of August 22, 2016, with a duration of twelve (12) months (the “Term”), although this could be subject to change, based on mutual agreement.

 

Employment Status

 

For the duration of the secondment you will continue to be an employee of Amicus Therapeutics. Your existing terms of employment with Amicus Therapeutics will remain in force during the secondment, subject to the variations set out in this letter. However in the event of any conflict between this Agreement and the Employment Agreement, (and notwithstanding clause 7.9 of the Employment Agreement), whilst the secondment is in place, this Agreement shall prevail.

 

For the avoidance of doubt, you will continue to report directly to John Crowley, Chairman & CEO, and your title will remain President & Chief Operating Officer.

 

Employment Duties

 

Please note that whilst on secondment to the UK, you do not have authority to conclude contracts on behalf of Amicus Therapeutics and you should not hold out any home office you use as an office of Amicus Therapeutics in the UK.

 

As part of your current role as President and COO of Amicus, your role while in the UK will include:

 

·                  Provide increased Senior Leadership Team / Executive presence in International during critical first year(s) of launch of lead product

·                  Lead Amicus’ continued globalization efforts to ensure global commercial operations are aligned between Corporate HQ and International HQ

 

1

 

·                  Exchange and implement management and leadership best practices between US and International locations

·                  Increase Amicus’ corporate presence in UK and Europe with key Ex-US stakeholders including media, patient advocacy and public policy groups

·                  Lead and expand Amicus investor base with UK and European investors

·                  Oversee the evaluation of global organizational structure to achieve Amicus goals

·                  Evaluate opportunities for global expansion in line with Amicus goals

 

Compensation/Benefits

 

Base Salary:

 

Your base salary during the secondment will be USD$427,450 (“Base Salary”), which equals your current annual base salary under the Employment Agreement.  Please see paragraphs below on “Withholding, Social Security and 401K” and “Tax Equalization and Tax Preparation” for details of applicable payroll deductions. You will be responsible for setting up a UK bank account and transferring the funds you need to the UK.

 

Insured Benefits:

 

You will continue to participate in Amicus Therapeutics’ benefits programs, as provided under the Employment Agreement, to the extent permitted by the relevant benefit plans.  It is not possible to continue cover under the Amicus Therapeutics Medical Plan, however whilst on secondment, you will be enrolled in the Aetna International Expat Trust Open Access Managed Choice POS — Global Prime Benefits Plan, which provides medical coverage, subject to the rules of the Plan as amended from time to time. A copy of the Plan is available from Amicus Therapeutics’ HR department and this will outline the extent of the cover and details of any applicable excesses and other terms.  Employee contributions to the cost of benefits programs in which you will be participating whilst on secondment, will continue to be withheld from your compensation.

 

Additional Benefits

 

You will receive the following benefits whilst you are on secondment, provided any pre-conditions to this Agreement have been satisfied:

 

	
Immigration fees
    	
 
    	
Full reimbursement, or direct payment of, immigration fees or costs for   you, your spouse/partner and accompanying dependents.
    
	
Travel to and from Host Country
    	
 
    	
Travel to and from the home to host location (Gerrard’s Cross, UK) at   the outset of the secondment and at the end of the secondment for you, your   spouse/partner, and accompanying dependents will be covered in accordance   with the Amicus Therapeutics’ T&E policy, as amended from time to time.
    
	
Relocation Allowance
    	
 
    	
A lump sum relocation allowance of $15,000 to assist with miscellaneous   transition expense and household good, which will be paid as soon as   administratively feasible following the later of the date of this Agreement   and the date you secure entry clearance to the UK. A lump sum relocation   allowance of $10,000 payable within the month of return to the United States   at the end of your assignment. This is a taxable item to you.
    
	
Automobile lease in Host Country
    	
 
    	
The cost to lease an automobile for one year in host country directly   paid by the company. Our assumption is that you will use your own vehicle for   business purposes and that you will be responsible for any road tax and   maintenance of the same and for any penalties, fines, parking charges and   congestion charges incurred. Fuel consumed on legitimate business travel 
    

 

2

 

	
 
    	
 
    	
will be reimbursed in accordance with the Company’s/Amicus   Therapeutics’ travel and expenses policy, (“T&E policy”) as amended from   time to time.
    
	
Automobile Insurance in host country
    	
 
    	
Monthly allowance of $400 per month to help offset automobile insurance   while in host country.
    
	
Transportation of family personal effects
    	
 
    	
Amicus will provide payment of, or reimbursement for, up to $5,000 per   year to third party for the transportation of family personal effects to and   from host country.
    
	
Temporary Storage or other incidental expenses
    	
 
    	
Reimbursement for unanticipated and unplanned moving/transportation   expenses, for example, temporary storage of household goods or parking, of up   to $2,000.
    
	
Housing in host country
    	
 
    	
Amicus will provide direct payment to leasing agent for the rental of   suitable housing and furnishings in host country of your choosing.
    
	
Utilities
    	
 
    	
Amicus will reimburse cost of utilities for leased housing while   residing in the UK.
    
	
Per Diem for incidental expenses
    	
 
    	
Amicus will provide a per diem amount of $98 to cover meals and   incidental expenses.
    
	
Home Leave
    	
 
    	
Amicus Therapeutics will reimburse airfare costs for one home leave   trip within every twelve (12) months whilst on secondment for you, your   spouse/partner and accompanying dependents, subject to the terms of Amicus   Therapeutics’ T&E policy, as amended from time to time.
    
	
Education Assistance
    	
 
    	
Amicus Therapeutics will provide tuition and Fees for two children to   attend Private School of parents’ choosing in host country.
    
	
Emergency Leave
    	
 
    	
Emergency Leave provided in the event of a serious illness or death to   a member of your or your spouse/partner’s immediate family. Immediate family   is defined as parents or siblings Amicus Therapeutics will reimburse   round-trip air travel to the appropriate location, in accordance with Amicus   T&E Policy as amended from time to time.
    
	
Repatriation Benefits
    	
 
    	
Contingent on your continued employment with Amicus Therapeutics at the   end of your secondment, or should Amicus Therapeutics terminate your   employment whilst you are on secondment without “Cause,” or should you   terminate your employment for “Good Reason,” (as such terms are defined in   the Employment Agreement), travel from host to home location for you, your   spouse/partner, and accompanying dependents will be covered in accordance   with the Amicus Therapeutics’ T&E policy, as amended from time to time.   This will include the transportation of personal items up to $5,000. 

 

In the event of your resignation, or termination of your employment   with Amicus Therapeutics for “Cause” (as such term is defined in the   Employment Agreement) while you are on secondment, you will be required to   pay the expenses of returning yourself, your family and your personal effects   back to the Princeton, NJ, USA and Amicus Therapeutics shall not be required   to contribute to the cost.
    
	
Tax Gross Up
    	
 
    	
If any of the items above are deemed to be taxable to you, unless   otherwise noted, items will be grossed up to ensure they are tax neutral to   you.
    

 

3

 

International Assignment support

 

Amicus Therapeutics has selected Mobility Services International (MSI), to assist with your transitional, on-going assignment, and repatriation needs. You will be assigned a MSI International Assignment Manager (IAM) who will assist in coordinating all assignment related services.

 

Visa/Work Permit

 

Amicus Therapeutics will pay for all costs of assignment-related Visas and Work Permits. The cost of physical examinations and immunizations mandatory by the host country will also be covered. MSI will manage the entire Immigration process on behalf of Amicus Therapeutics.

 

Vacation/Holidays:

 

Once you start the secondment and for the remainder of this calendar year, you will continue to be eligible for vacation in line with Amicus Therapeutics’ vacation policy, save that you will be entitled to English public holidays rather than public holidays observed in the U.S. With effect from 1 January 2017, the Amicus Therapeutics vacation policy will cease to apply whilst you are on secondment and instead you will be eligible for 25 days’ vacation in addition to English public holidays in each UK holiday year whilst the secondment is ongoing, but with a pro-rata reduction where less than a full holiday year is worked in the UK. This is in line with the vacation policy observed by the Company. The Company’s holiday year runs from 1 January to 31 December.

 

Vacation should be taken at times agreed with the CEO, John Crowley. Up to 5 days’ unused vacation may be carried forward from one holiday year to the next with the agreement of the Company’s CEO, John Crowley, but carried forward vacation must be used within the first three months of that year or it will be lost.

 

Except on termination of employment, whilst you are in the UK, Amicus Therapeutics will not pay holiday pay in lieu of your taking vacation to which you are entitled.

 

Pension

 

As you are continuing to be paid through the Amicus payroll system in the United States, you will continue to participate in Amicus Therapeutics’ 401K plan as opposed to participating in any UK pension arrangements. If you decide at a later date to participate in the Company’s pension arrangements in the UK, then this will be instead of rather than in addition to your current 401K arrangements.

 

Sick leave and sick pay

 

Whilst you are on secondment, the US sick leave and sick pay rules will cease to apply and will be replaced with the following:

 

If you are ill or unable to work for any reason you will notify the Head of Human Resources, International as soon as possible on the first day of absence of the reasons for your absence and how long it is likely to last. You will be required to complete self-certification forms in respect of any period of absence lasting less than 7 days and to provide a medical Fit Note for any period of incapacity of more than seven days (including weekends). Further Fit Notes must be provided to cover any further periods of incapacity.

 

Provided you comply with these sickness absence procedures you will continue to receive your full salary and contractual benefits during any absence from work due to illness or injury for an aggregate of up to 40 working days in any period of 12 months. Such payments will be inclusive of any statutory sick pay that may be due but the Company/Amicus Therapeutics may deduct from any such payments the amount of any social security or other benefits that you may be entitled to receive.

 

No sick pay will be paid (except statutory sick pay, if payable) on any day when:

 

4

 

(a) a hearing is pending which relates to any aspect of your conduct or performance and which could result in the imposition of a warning, dismissal or other sanction; or

(b) you have been told, whether formally or informally, that there are concerns about any aspect of your conduct or performance which could result in a disciplinary hearing; or

(c) you are in breach of your obligations in relation to medical examinations and reports set out below.

 

If damages for loss of earnings are recoverable from any third party in relation to such incapacity, any payments under this clause will constitute a loan repayable to the Company/Amicus Therapeutics (as the case may be) on demand at such time as you receive such third party payment (not exceeding damages recovered).

 

In order to assess your ability to carry out your duties and your fitness for work, you consent to undergo medical examinations (at the Company’s/Amicus Therapeutics’ expense) by a doctor or other medical practitioner appointed by the Company and you agree to provide to that doctor copies of your medical records. The results of the examination may be disclosed to the Company and Amicus Therapeutics and their respective professional advisers and they may in turn discuss such results with the relevant doctor. Alternatively, you may be asked to obtain a medical report from your GP or another person responsible for your clinical care and to provide this to the Company. This clause is without prejudice to any UK statutory rights you may have, including any rights under the Access to Medical Reports Act 1988

 

Deductions from pay

 

For the purposes of the Employment Rights Act 1996, Sections 13-27, you hereby authorize the Company/Amicus Therapeutics to deduct from your salary (and/or other sums due under this Agreement), any sums due from you to the Company or to Amicus Therapeutics, including without limitation, any over payments, (whether made by mistake or by misrepresentation), loans or advances made to you by the Company or Amicus Therapeutics, the cost of repairing any damage or loss to the Company’s or Amicus Therapeutics’ property caused by you and any losses suffered by the Company or Amicus Therapeutics as a result of any negligence or breach of duty on your behalf, as well as any applicable taxes and other deductions required by law in respect of the remuneration payable to you by the Company and/or Amicus Therapeutics.

 

Repayment Agreement

 

Amicus Therapeutics will be investing in your relocation, which includes reimbursement of and/or advancing certain expenses to you and/or any third parties on your behalf as mentioned in this Letter of Assignment. In the event that you voluntarily resign your employment from Amicus Therapeutics other than for Good Reason or if your employment with Amicus Therapeutics is involuntarily terminated due to Cause, you hereby agree to repay Relocation Expenses, which includes the costs associated with relocating your personal effects and tuition fees for the children, as follows:

 

·                  If termination of employment occurs within the first 12 months of the secondment, then you agree to repay AMICUS THERAPEUTICS one hundred percent (100%) of such Relocation Expenses; OR

·                  If the secondment is extended and the termination of employment occurs between 13 months and 24 months after your secondment start date, then you agree to repay Amicus Therapeutics fifty percent (50%) of such Relocation Expenses.

 

Withholding, social security and 401K

 

Amicus Therapeutics will continue to pay employer social security contributions in the US in respect of you and to pay the employer match on your 401K plan, on the same basis as prior to the start of the secondment. You will be responsible for all required US, federal and state tax payments or other deductions. You may also be subject to income tax and any deductions required by applicable law with in the UK. These will be made by

 

5

 

the Company at source. Amicus Therapeutics and the Company shall therefore be entitled to withhold from amounts payable or benefits accorded to you under this Agreement all federal, state and local income, employment and other taxes, as and in such amounts as may be required by applicable law. Amicus Therapeutics has applied for a Certificate of Coverage in respect of you. If obtained, no deductions will be made from your remuneration in respect of UK employee national insurance contributions.

 

Tax Equalization and Tax Preparation

 

You will be tax equalized while on secondment. Tax Equalization ensures that you do not incur a higher or lower tax liability due to the international assignment. Amicus Therapeutics has retained the services of Price Waterhouse Coopers (PWC) to support all expatriate tax matters. PwC will calculate a Hypothetical Tax Liability that will be deducted from your payroll. At the end of each tax year, you will be issued a Hypothetical Tax Settlement to calculate any under or overpayment of you Hypothetical liability.

 

You will also be provided the professional services of a tax consultant to prepare any home and/or host country tax returns during the secondment and for the tax year after the year in which the secondment ends. However it shall be your sole responsibility to file the returns in each of the taxing jurisdictions.

 

Place of work

 

Whilst on secondment, your normal place of work will be the Company’s offices in Gerrard’s Cross the precise location of which may change from time to time. However it is anticipated that you will need to travel extensively within the UK, the EU, Asia, and other overseas locations on the business of the Company and the Group.

 

Hours of work

 

Normal UK office hours are 37.5 hours per week, 7.5 hours daily between Monday to Friday. However in your role you are required to work such additional hours as may be needed for the efficient performance of your duties, with no entitlement to overtime or additional payments. You agree that the limit on average weekly working time set out in Regulation 4(1) of the Working Time Regulations 1998 will not apply to you, although you may withdraw your consent on giving the Company three months’ prior written notice.

 

Expense Reimbursement Management Process

 

The Company will reimburse any travelling, hotel, entertainment and other out-of-pocket expenses properly and reasonably incurred by you in connection with the discharge of your duties whilst you are on secondment, subject to the terms of the Company’s T&E policy, as amended from time to time and in accordance with the rules set out below.

 

For tax planning and preparation purposes, it is critical that all expenses related to your international assignment be properly recorded and reported. Within 30 days of incurring an expense, you must complete an online relocation expense report for those services not paid directly by Amicus Therapeutics and attach scanned receipts.

 

Any taxable reimbursement of business or other expenses as specified under this Agreement shall be subject to the following further conditions: (1) the expenses eligible for reimbursement in one taxable year shall not affect the expenses eligible for reimbursement in any other taxable year; (2) the reimbursement of an eligible expense shall be made no later than the end of the calendar year after the year in which such expense was incurred; and (3) the right to reimbursement shall not be subject to liquidation or exchange for another benefit.

 

6

 

Data Protection

 

You consent to both Amicus Therapeutics and the Company holding and processing both your personal data and sensitive personal data, (the latter includes information relating to your physical or mental health and any unspent criminal convictions), for all purposes relating to your employment. In particular you agree that Amicus Therapeutics and/or the Company can hold, process and disclose personal and sensitive personal data for the all purposes connected with staff administration including to: (a) pay and review your remuneration and other benefits; (b) provide and administer any benefits due to you; (c) determine your fitness to work, or your entitlement to sick pay or other leaves of absence; (d) provide information to HM Revenue & Customs, the IRS or any other taxation authorities, the police, benefit and payroll providers, relevant regulatory bodies, the Company’s legal advisers, any potential purchasers of the Company or any business area in which you work and to any investors or potential investors in the Company, regardless of the geographical location in which any of the foregoing are located; (e) administer and maintain personnel records (including disciplinary, sickness and other absence records); carry out performance reviews, disciplinary or grievance procedures; (f) give references to future employers; and (g) assist with any investigations being undertaken by Amicus Therapeutics and/or the Company and/or any external regulatory authority, whether in the UK, the US or any other country. You also consent to the transfer of personal and sensitive personal data concerning you for all these purposes to countries outside the EEA and, in particular, to the HR, legal and payroll departments of Amicus Therapeutics in the United States and to the inclusion of such data in HR databases which may be located or accessed from outside the EEA.

 

Company Policies

 

During the secondment you will be required to abide by any Company rules, policies and procedures as amended from time to time which are applicable to employees at your level of seniority notwithstanding the fact that such policies do not form part of your Employment Agreement and do not have contractual force.

 

Confidentiality, Disclosure and Non-Competition

 

Whilst you are on secondment the provisions of the Amicus Therapeutics, Inc., Confidentiality, Disclosure and Non-Competition Agreement (“the Confidentiality etc Agreement”) dealing with Confidential Information and Non-Competition shall be replaced with the provisions below. The provisions below shall survive the termination of your secondment and shall continue to supercede the equivalent provisions in the Confidentiality etc Agreement in the event that you breach any of the said provisions in the UK and Amicus Therapeutics seeks to enforce its rights before the courts of England and Wales. In all other respects however, following the termination of your secondment, the provisions on Confidentiality and Non-Competition set out in this letter shall lapse and the equivalent provisions of the Confidentiality etc Agreement shall apply.

 

Confidential Information

 

You will not, (save in the proper course of your duties, or as specifically authorized by Amicus Therapeutics or  the Company), either during your employment, or at any time after its termination (howsoever arising), directly or indirectly:

 

(a) use any Confidential Information;

(b) disclose or permit the disclosure of Confidential information to any person, company or organization whatsoever, or

(c)  make or use any copies of the same.

 

You are responsible for protecting the confidentiality of the Confidential Information and shall:

 

(i)   use your best endeavors to prevent the use or communication of any Confidential information by any unauthorized   person, company or organization; and

(ii)  inform the Company and Amicus Therapeutics immediately upon becoming aware, or  suspecting, that any such person, company or organization has access to or has used any Confidential Information.

 

7

 

The  restrictions above shall  not  apply to  information  which  you  or another  person  may be ordered  to disclose  by a court or tribunal of competent jurisdiction, or which  you  disclose  pursuant to and in accordance with the Public Interest Disclosure Act 1998, provided you have complied with the Company’s policy (if any) from time to time, regarding such disclosures, or as may be required by law.

 

You must not publish any literature, deliver any lecture or make any communication to the media (including the press, radio, or television), or on the internet, relating to the business of Amicus Therapeutics or any other Group Company, without the prior written authority of your manager.

 

Non-Competition

 

You will have dealings in the course of your employment with and influence over the employees, customers, distributors, wholesalers, clinical investigators, prescribers of products and suppliers of Amicus Therapeutics, the Company and other Group Companies and have access to confidential information about their respective businesses. In order to protect the goodwill, customer connection, stable workforce and confidential information of Amicus Therapeutics, the Company and other Group Companies, you agree, without prejudice to any other duty implied by law or equity that, whilst you are on secondment and for the period of 12 months after the termination of your secondment (“the Restricted Period”) howsoever caused, you will not, without the prior written approval of Amicus Therapeutics, in any capacity and whether directly or indirectly:

 

(a) on behalf of any Competing Business, solicit or endeavor to solicit, entice away, or endeavor to entice away from Amicus Therapeutics, the Company or any other Group Company, any person, firm, company or organization who or which is at the Relevant Date, or was at any time in the twelve months preceding the Relevant Date, a customer, distributor, wholesaler, clinical investigator or prescriber of Restricted Products of Amicus Therapeutics, the Company or any other Group Company and with whom you had business dealings in the course of your employment in the 12 months prior to the Relevant Period;

 

(b) on behalf of any Competing Business, have business dealing with any person, firm, company or organization who or which is at the Relevant Date, or was at any time in the twelve months prior to the Relevant Date, a customer, distributor, wholesaler, clinical investigator or prescriber of Restricted Products of the Company or any Group Company, and with whom you had business dealings in the course of your employment in the twelve months prior to the Relevant Date;

 

(c) solicit or endeavor to solicit, entice away or endeavor to entice away from Amicus Therapeutics, the Company or any other Group Company any person who is the twelve months prior to the Relevant Date was engaged as a consultant, appointed an officer or employed as a director or any other senior employee and with whom you had business dealings in the course of your employment at any time in the twelve months prior to the Relevant Date, to become employed by any Competing Business, whether or not such person would commit a breach of contract by reason of leaving and you will not authorize or knowingly approve the taking of such actions by any other person, firm, company or organization.

 

(d) be employed or engaged, (whether as an employee, officer, partner, worker, or independent contractor), in any part of any company, firm or business, which part competes in the UK with the any business of Amicus Therapeutics, the Company or any Group Company, with which business you were materially involved in the twelve months prior to the Relevant Date. For the avoidance of doubt, nothing in this clause shall prevent you holding up to 3% of the shares or securities of any company for bona fide investment purposes, or from being employed or engaged by a company, firm or business, in a capacity which does not involve you in any activities with compete with those of Amicus Therapeutics, the Company or any other Group Company with which you were materially involved in the twelve months prior to the Relevant Date.

 

If any restriction in this paragraph is held to be invalid or unenforceable by a court of competent jurisdiction, it is intended and understood by the parties that such invalidity or unenforceability will not affect the remaining restrictions, or the validity of the rest of the Agreement and that if any such restriction would be valid if some part thereof (including a term defined elsewhere in this Letter, were deleted), such restrictions shall apply with such modification as may be necessary to make them effective.

 

8

 

In this paragraph, “Competing Business” means any business which competes or is preparing to compete with any business carried on by Amicus Therapeutics, the Company or any other Group Company in which you have been involved to a material extent during the Relevant Period.

 

“Relevant Date” means the earlier of: (i) the date on which the act prohibited by this paragraph occurs; and (ii) the date on which your secondment terminates;

 

“Restricted Products” means products of the Company or any Group Company with which you were involved in the course of your employment in the twelve months prior to the Relevant Date or in respect of which you had confidential information at the Relevant Date.

 

Monitoring of Communications

 

All communications, whether by email, fax, or any other means, which are transmitted, undertaken or received (a) from any home office via a Citrix, VPN or similar connection to the Company’s or Amicus Therapeutics’ systems, or (b) using the Company’s or Amicus Therapeutics’ equipment, or (c) on Company premises, will be treated by the Company and Amicus Therapeutics as work-related and are subject to occasional interception, recording and monitoring without further notice. Likewise your use of the internet using the Company’s or Amicus Therapeutics’ equipment or internet connection may also be monitored. You should not therefore regard any such communications as private. Interception, recording and monitoring of communications is intended to protect the Company’s/Amicus Therapeutics’ business interests, for example but without limitation, for the purposes of quality control, security of communication and IT systems, record-keeping and evidential requirements, detection and prevention of criminal activity or misconduct and to assist the Company and Amicus Therapeutics to comply with relevant legal requirements. Monitoring may also be required if you are absent from work, so that your work can be properly attended to. Intercepted communications may be transferred to Amicus Therapeutics in the US and used as evidence in disciplinary or legal proceedings, including in any such action against you. By transmitting, undertaking or receiving communications using Company property or on Company premises, you consent to the above terms.

 

Business Conduct

 

It is understood that you will not engage in any employment or business enterprises that would in any way conflict with your service to Amicus Therapeutics, the Company, or any other Group Company.  You will continue to conduct your business affairs with integrity and in accordance and compliance with all applicable laws in the United Kingdom.

 

Disciplinary and grievance procedures

 

In the event that you wish to raise a grievance or are dissatisfied with a disciplinary decision relating to you whilst you are on secondment, the parties will follow any disciplinary and/or grievance procedure applicable at the Company, save that Amicus Therapeutics may substitute its own managers to deal with meetings under the policy if it considers it appropriate to do so. These procedures do not have contractual force and may be varied from time to time.

 

Termination of Employment

 

(a) During the secondment, either Amicus Therapeutics or you may terminate your employment by giving the other party written notice which is equal to the greater of the statutory minimum notice period required by English law, or any longer period of notice set out in the Employment Agreement. In addition, whilst you are on secondment, Amicus Therapeutics may terminate your employment at any time by making a payment of basic salary in lieu of any period of notice to which you may be entitled. In the alternative, during your notice period,

 

9

 

or part of it, Amicus Therapeutics shall not be required to provide you with work and may require you (a) to carry out different duties from your normal duties and/or (b) cease carrying out your duties altogether, or having any business dealings with Amicus Therapeutics’ or the Company’s employees, suppliers, customers and agents and (c) may exclude you from any of its premises or those of the Company. You will continue to receive your salary and all contractual benefits provided by your employment. During such period you may not be engaged or employed by, or take up any office or partnership in, any other company, firm, or business, or trade on your own account without Amicus Therapeutics’ written permission and will resign from all offices you hold within the Group. In all other respects the termination provisions of the Employment Agreement shall apply. For the avoidance of doubt, any release required to be entered into as a condition precedent of payment of any severance under the Employment Agreement, may include the execution of a Settlement Agreement with Amicus Therapeutics and the Company under English law.

 

(b) Termination of your employment whilst you are on secondment, automatically brings the secondment to an end.

 

(c) You should also note that the Company may be required to report the termination of your employment and/or the termination of the secondment to the immigration authorities in the UK and that the work permit issued to the Company does not entitle you to work for another employer in the UK.

 

(d) Prior to your return to the United States, you are responsible for ensuring that you have given required notice to end any relevant contracts you have entered into in the UK (for example any rental contract relating to your accommodation, agreements with utility companies etc). In addition, you are responsible for making your own arrangements for your home country housing prior to repatriation.

 

(e) On the completion of your secondment, all variations to your Employment Agreement as set out in this letter, applicable during the period of your secondment will cease, save as set out in this Letter.

 

Termination of the Secondment

 

Amicus Therapeutics reserves the right to terminate your secondment at any time before the expected end of the secondment period and for any reason. However it will not usually do so without first consulting you and giving you two months’ prior written notice.

 

Return of Amicus Property

 

Upon the termination of the Secondment Agreement for any reason, or at the Company’s earlier request, you will return to the Company all property belonging to the Company or relating to its affairs which is in your custody, possession or control, including but not limited to all records, documents, files, research and development reports and data, test results, customer lists and databases, customer contracts, price lists, computer software and all equipment together with all copies of the same and no further copies may be taken without the Company’s written consent. If your employment is ending at the same time, you must also return to Amicus Therapeutics any of its property which is in your possession, custody and control, together with all copies thereof and you may not take any further copies without the consent of Amicus Therapeutics’ General Counsel.

 

Definitions

 

“Confidential Information” means all and any information, in whatever form, of or relating to Amicus Therapeutics, or any member of the Group, including the Company, which you have obtained by virtue of your employment with Amicus Therapeutics. Confidential information incudes (but not limited to):

 

a)             unpublished research information, clinical and other test results and/or information relating to confidential projects being undertaken by any member of the Group, (including such information that

 

10

 

has commercial value to the Group from a negative viewpoint, such as the results of research which might indicate that development of  new therapies  will be unsuccessful);

b)             unpublished formulae,  patterns,  compilations,  programs,  devices,  methods, techniques, or processes or;

c)              technical procedures, engineering and product specifications;

d)             financial information, results and forecasts, sales  targets  and statistics, market share and pricing statistics, profit margins, price lists,  discounts, credit and payment policies and procedures;

e)              information relating to business methods,  corporate  plans,  business strategy, marketing plans, management systems, maturing new business opportunities, tenders, advertising and promotional material;

f)               information  relating  to  and  details  of  customers,  prospective  customers, suppliers   and   prospective   suppliers   including   their   identities and the identity of key contacts at each of them, their business requirements and contractual arrangements and negotiations with any member of the  Group;

g)              details of the terms of employment including remuneration of employees, officers, workers and consultants to the Group, but excluding any confidentiality and post-termination restrictions applicable to them;

h)             information relating to trade secrets, research activities, development projects, inventions, designs, know-how, technical specification and other technical information in relation the development or supply of any future product or service of any member of the Group and information concerning the intellectual property portfolio and strategy of any member of the Group; and

i)                 any information in respect of which any member of the Group is bound by an obligation of confidence to a third party.

 

Confidential information shall not include any information which:

 

	
i)
    	
is part of your own   stock in trade;
    
	
ii)
    	
is readily   ascertainable to persons not connected with any member of the Group without   significant expenditure of labour, skill or money; or
    
	
iii)
    	
which becomes available   to the public generally other than by reason of a breach by you of your   obligations set out in this letter.
    

 

“Group Company” means any company which from time to time is a subsidiary or holding company of Amicus Therapeutics or a subsidiary of such holding company and the terms “subsidiary” and “holding company” shall have the meanings ascribed to them in section 1159 of the Companies Act 2006. Any reference to the Group means Amicus Therapeutics and its Group Companies.

 

Miscellaneous

 

(a) This Agreement supersedes any and all prior or contemporaneous verbal, written or implied agreements, understandings or communications between you and Amicus Therapeutics and/or the Company regarding the terms of your assignment to the UK and constitutes the entire agreement between you and them. You warrant that by entering into this Agreement you are not relying upon any representation not expressly set out in this Agreement.

 

(b) Any modification or waiver of any provision of this Agreement must be made in writing and signed by both parties.

 

(c) For the avoidance of doubt if you were to terminate your employment as a consequence of your secondment to the UK, this shall not constitute a termination for “Good Reason” under the terms of the Employment Agreement, notwithstanding the change in geographical location.

 

(d) This Agreement will be governed by, and construed in accordance with, the laws of England and Wales, whose courts shall have non-exclusive jurisdiction over any and all disputes arising out of, or in connection with it.

 

11

 

The conditions of the assignment may be subject to change.  You will be notified of any changes in writing.

 

Bradley, I know you will contribute significantly to our success in the United Kingdom and I look forward to having you join our team.

 

Sincerely,

 

 

	
/s/ Kurt J. Andrews
    	
 
    
	
 
    	
 
    
	
Kurt J. Andrews
    	
 
    
	
Senior Vice President
    	
 
    
	
Human Resources
    	
 
    

 

 

	
Cc: Daphne Quimi,   Senior Vice President, Finance
    
	
Cc: Jane Machin, Head   of Human Resources, International
    

 

Signature

 

I have read through the attached this Letter of Secondment and understand the benefits that have been provided to me. My signature below indicates my awareness and agreement to all the terms herein and the variations to my Employment Agreement.

 

	
 
    	
 
    
	
Campbell, Bradley
    	
 
    
	
 
    	
 
    
	
/s/ Bradley Campbell
    	
 
    
	
Signature
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
Date: August 22,   2016
    	
 
    

 

12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00261-of-00352.parquet"}]]